Wellnex Secures TGA approval for Liquid Paracetamol plus Caffeine Soft Gel as it targets growth opportunities

Wellnex obtains market authorisation with the Therapeutic Goods Administration for Liquid Paracetamol plus Caffeine Soft Gel.

Wellnex has secured its fourth marketing authorisation from the TGA. Pic: Getty Images.

• Wellnex achieves Therapeutics Goods Administration authorisation for Liquid Paracetamol plus Caffeine Soft Gel

• Builds on company’s three other market authorisations by Australian regulator

• Market authorisation to further boost revenue opportunities

Special Report: Wellnex Life has achieved a key milestone with a new market authorisation by Australia’s Therapeutic Goods Administration for a liquid paracetamol plus caffeine soft gel.

Health and wellness company Wellnex Life (ASX:WNX) said the new approval followed successful submission of a pharmaceutical dossier with the TGA for the product.

The company now has four market approvals for its liquid soft gel portfolio, with others including:

• Liquid Paracetamol
• Liquid Paracetamol plus Ibuprofen; and
• Liquid Mini-Ibuprofen

Wellnex’s four market authorisations for a range of liquid soft gels validates the company’s philosophy of being either first or fast with innovative products for the consumer health market.

Driving revenue

The company said the latest market authorisation from the TGA would further drive revenue opportunities.

It builds on existing market authorisations, which were being used by domestic and international companies like Chemist Warehouse and Haleon, the latter being one of the largest global consumer healthcare businesses.

Haleon’s brands include Sensodyne toothpaste, Panadol and Advil painkillers and Centrum Vitamins.

“The approval of liquid paracetamol plus caffeine soft gel market authorisation is a great testament to the company and its internal capabilities,” managing director Zack Bozinovski said.

“This unique product will provide opportunities not only for use in the company’s own brands but also for licensing to third parties.”

Dual-UK listing in 2025

Wellnex is continuing to progress a dual listing on the London Stock Exchange to attract further institutional and retail investment as the company plans a global expansion.

Leading UK based broker SP Angel have been appointed as joint broker to the UK raise with Orana, who are being supported by Australian based Barclay Pearce Capital.

Wellnex reported record sales for November and December 2024 of $3 million per month, with 56% of sales generated from the company’s high margin brands.

This article was developed in collaboration with Wellnex Life, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as Wellnex Secures TGA approval for Liquid Paracetamol plus Caffeine Soft Gel as it targets growth opportunities